| Dr Kenneth Alan Otto Jr, MD | |
|
1266 E Sherman Blvd, Muskegon, MI 49444-1847 | |
| (231) 739-9009 | |
| (231) 733-0566 |
| Full Name | Dr Kenneth Alan Otto Jr |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1266 E Sherman Blvd, Muskegon, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164403838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 4301403805 (Michigan) | Primary |
| Entity Name | Shoreline Ophthalmology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679643670 PECOS PAC ID: 3678537628 Enrollment ID: O20060613000017 |
News Archive
Alere Inc., a global leader in rapid diagnostics, announced today two transactions that further strengthen the Company's focus on its core business strategy.
A new study has found that genes cause about 1 in 10 cases of chronic kidney disease in adults, and identifying the responsible gene has a direct impact on treatment for most of these patients.
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found.
Whether you prefer a cool summer night with a gentle breeze or a crystal clear and still winter day, the human perception of temperature, or thermal comfort, whilst largely dependent on the temperature itself, involves several other climate variables, such as humidity and wind speed.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kenneth Alan Otto Jr, MD 1266 E Sherman Blvd, Muskegon, MI 49444-1847 Ph: (231) 739-9009 | Dr Kenneth Alan Otto Jr, MD 1266 E Sherman Blvd, Muskegon, MI 49444-1847 Ph: (231) 739-9009 |
News Archive
Alere Inc., a global leader in rapid diagnostics, announced today two transactions that further strengthen the Company's focus on its core business strategy.
A new study has found that genes cause about 1 in 10 cases of chronic kidney disease in adults, and identifying the responsible gene has a direct impact on treatment for most of these patients.
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found.
Whether you prefer a cool summer night with a gentle breeze or a crystal clear and still winter day, the human perception of temperature, or thermal comfort, whilst largely dependent on the temperature itself, involves several other climate variables, such as humidity and wind speed.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 5 days ago
Dr. Mark Stephen Kinziger, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1266 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-739-9009 Fax: 231-733-0566 | |
Mr. David Alan Goran, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1150 E Sherman Blvd, Ste 1500, Muskegon, MI 49444 Phone: 231-737-9378 Fax: 231-737-1023 | |
Mrs. Leeann Salot Webster, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1266 East Sherman Blvd, Muskegon, MI 49444 Phone: 231-739-9009 Fax: 231-733-0566 | |
Dr. Nathan Paul Reed, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1266 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-739-9009 Fax: 231-733-0566 | |
Dr. John Nicholas Oltean, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1266 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-739-9009 Fax: 231-733-0566 | |
Dr. David James Rawlinson, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1266 E Sherman Blvd, Muskegon, MI 49444 Phone: 231-739-9009 |